Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ectopic ACTH Syndrome Clear all
Completed Phase 3 Interventional Results available

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

NCT01371565
View directory record Official record
Conditions
Cushing's Disease, Cushing's Syndrome
Interventions
Mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Hollywood, Florida • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 25, 2026, 3:01 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome

NCT06635629
View directory record Official record
Conditions
Cushing Syndrome
Interventions
Desmopressin, Dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 25, 2026, 3:01 AM EDT
Completed No phase listed Observational

Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery

NCT02922257
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Rochester, Minnesota • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 25, 2026, 3:01 AM EDT
Completed No phase listed Observational

Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome

NCT00001453
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 25, 2026, 3:01 AM EDT
Completed No phase listed Observational

Diagnostic Performance of Screening Tests for Cushing s Syndrome

NCT00361777
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 100 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2019
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 25, 2026, 3:01 AM EDT
Terminated Phase 2 Interventional Results available

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

NCT00958841
View directory record Official record
Conditions
Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
Interventions
pasireotide LAR
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 25, 2026, 3:01 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

NCT01374906
View directory record Official record
Conditions
Cushing's Disease
Interventions
pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 25, 2026, 3:01 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

NCT02804750
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
CORT125134
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Laguna Hills, California • Aurora, Colorado • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 25, 2026, 3:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

NCT05347979
View directory record Official record
Conditions
Cushing Syndrome, Neoplasms
Interventions
Dabigatran Etexilate, Relacorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 25, 2026, 3:01 AM EDT
Completed No phase listed Observational

Study of Adrenal Gland Tumors

NCT00005927
View directory record Official record
Conditions
Adrenal Gland Neoplasm
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 70 Years
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 3:01 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00936741
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 25, 2026, 3:01 AM EDT
Not listed No phase listed Observational

Study of Depression, Peptides, and Steroids in Cushing's Syndrome

NCT00004334
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
20 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 3:01 AM EDT
Completed Phase 3 Interventional Results available

Open-label Treatment in Cushing's Syndrome

NCT03621280
View directory record Official record
Conditions
Cushing Syndrome, Cushing Disease
Interventions
Levoketoconazole
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Atlanta, Georgia • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 25, 2026, 3:01 AM EDT
Withdrawn Phase 3 Interventional

Mifepristone in Children With Refractory Cushing's Disease

NCT01925092
View directory record Official record
Conditions
Cushing's Disease
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
6 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Oct 25, 2026, 3:01 AM EDT
Completed No phase listed Observational

Study of Cushing's Syndrome Not Related to ACTH Production

NCT00006278
View directory record Official record
Conditions
Cushing's Syndrome, Healthy
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 3:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Heart Disease Risk Factors in Major Depression

NCT00001969
View directory record Official record
Conditions
Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 3:01 AM EDT
Completed Phase 4 Interventional Results available

Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism

NCT01990560
View directory record Official record
Conditions
Mild Hypercortisolism
Interventions
Mifepristone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 25, 2026, 3:01 AM EDT
Terminated Phase 2 Interventional Results available

A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome

NCT03053271
View directory record Official record
Conditions
Cushing Syndrome
Interventions
ATR-101, Placebo
Drug
Lead sponsor
Millendo Therapeutics US, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts • Cleveland, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 25, 2026, 3:01 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

NCT03374215
View directory record Official record
Conditions
Adrenal Gland Neoplasm, Hypertension, Bone Diseases, Metabolic, Cardiovascular Disease, Hyperinsulinemia
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
7 Years to 70 Years
Enrollment
1,150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 3:01 AM EDT
Completed No phase listed Observational

Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

NCT00001452
View directory record Official record
Conditions
Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease, Peutz-Jeghers Syndrome
Interventions
oCRH
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 70 Years
Enrollment
1,387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 3:01 AM EDT
Terminated No phase listed Observational

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

NCT00796783
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Cushing's syndrome confirmation
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
3
States / cities
Escondido, California • Hollywood, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 25, 2026, 3:01 AM EDT
Recruiting Phase 2 Interventional

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

NCT07296484
View directory record Official record
Conditions
Type 2 Diabetes, Cortisol Excess
Interventions
clofutriben, Placebo
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
61
States / cities
Chandler, Arizona • Tucson, Arizona • Fountain Valley, California + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 3:01 AM EDT
Recruiting No phase listed Observational

A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement

NCT06430528
View directory record Official record
Conditions
Endogenous Cushing Syndrome, Adrenal Insufficiency, Hypercortisolism
Interventions
Osilodrostat
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 3:01 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.

NCT03277690
View directory record Official record
Conditions
Endogenous Cushing's Syndrome
Interventions
Levoketoconazole, Placebo
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 25, 2026, 3:01 AM EDT